Few studies have evaluated the impact of new comorbidities, fragility and disability indices on transcatheter aortic valve replacement (TAVI) outcomes. This study analyzes Medtronic CoreValve U.S. Pivotal patients to develop a new, simpler scoring system to use in addition to the standard assessment of TAVI patients. A multidisciplinary heart team used objective criteria, the<a href="https://solaci.org/en/2016/07/28/a-new-score-to-predict-post-tavi-mortality/" title="Read more" >...</a>
TAVI with Evolut R device in low risk patients
Live Case Broadcasted by TBR Productions from Toulouse, France to Rio de Janeiro, Brazil, where took place the SOLACI-SBHCI 2016 Congress. Panelists: Rafael Cavalcante e Silva – BRAZIL, Patrick W. Serruys – UK, Samir Kapadia – USA, Jorge Atilio Belardi – ARGENTINA.
Extreme Valve Calcification in TAVI might compromise technical success
Original Title: Ballon-Expandable Trancatheter Aortic valve Replacement in Patients whit Extreme Aortic Valve Calcification. Reference: Yigal Abramowitz, et al. Catetherization and Cardiovascular Intervention 2016;87:117-1179. Courtesy of Dr. Carlos Fava. Transcatheter aortic valve replacement (TAVI) emerged as a valid option to treat high risk inoperable patients. A group of these patients presents extreme valve<a href="https://solaci.org/en/2016/06/16/extreme-valve-calcification-in-tavi-might-compromise-technical-success/" title="Read more" >...</a>
Low gradient and LV Dysfunction: TAVI or not?
Original Title: Impact of ejection fraction and aortic valve gradient on outcomes of transcatheter aortic valve replacement. Reference: Baron SJ et al. J Am Coll Cardiol. 2016;67:2349-2358. Low aortic valve gradient and left ventricular dysfunction are frequent in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVI) but only low aortic valve<a href="https://solaci.org/en/2016/06/02/low-gradient-and-lv-dysfunction-tavi-or-not/" title="Read more" >...</a>
Bad prognosis in patients with aortic regurgitation post TAVI
Original Title: Aortic Regurgitation Following Transcatheter Aortic Valve Replacement: Impact of Preprocedural Left Ventricular Diastolic Filling Patterns on Late Clinical Outcomes. Reference: Amir Halkin, et al. Catheterization Cardiovascular Intervention 2016;87:1156-1163. Courtesy of Dr. Carlos Fava. Even though the mechanisms underlying post TAVI aortic regurgitation (ARpost) remain unclear, there is no question this complication is<a href="https://solaci.org/en/2016/06/01/bad-prognosis-in-patients-with-aortic-regurgitation-post-tavi/" title="Read more" >...</a>
Post TAVI pacemaker implantation does not increase mortality
Original Title: Impact of New-Onset Left Bundle Branch Block and Periprocedural Permanent Pacemaker Implantation on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. A Systematic Review and Meta-Analysis. Reference: Ander Regueiro et al. Circ Cardiovasc Interv. 2016 May;9(5). Available data on the clinical impact of the new-onset left bundle branch block (LBBB) and<a href="https://solaci.org/en/2016/05/30/post-tavi-pacemaker-implantation-does-not-increase-mortality/" title="Read more" >...</a>
Low risk patients: TAVI or surgical replacement?
Original Title: Transcatheter Aortic Valve Implantation Compared With Surgical Aortic Valve Replacement in Low-Risk Patients. Reference: Stefano Rosato et al. Circ Cardiovasc Interv. 2016 May;9(5):e003326. The proved efficacy of transcatheter aortic valve implantation (TAVI) in high risk patients is leading the expansion of its indication for lower risk patients. All the same, compared to the<a href="https://solaci.org/en/2016/05/27/low-risk-patients-tavi-or-surgical-replacement/" title="Read more" >...</a>
TriGuard: NeuroProtection Device during TAVI
Original Title: A Patient Level Pooled Analysis of NeuroProtection with the TriGuard Embolic DEFLECTion Device Compared to Unprotected Transcatheter Aortic Valve Replacement. Presenter: Alexandra Lansky This work was designed to assess the safety and efficacy of the TriGuard device as a complement during transcatheter aortic valve implantation (TAVI) compared to no protection in a<a href="https://solaci.org/en/2016/05/20/triguard-neuroprotection-device-during-tavi/" title="Read more" >...</a>
TAVI at 10 Years: First Study to Assess TAVI Long Term Durability
Original Title: First look at long-term durability of transcatheter heart valves: Assessment of valve function up to 10 years after implantation. Presenter: Danny Dvir. Transcatheter aortic valve implantation (TAVI) is being used in increasingly younger patients at low surgical risk, which is why longer survival is expected. The durability of transcatheter aortic prostheses has<a href="https://solaci.org/en/2016/05/19/tavi-at-10-years-first-study-to-assess-tavi-long-term-durability/" title="Read more" >...</a>
TAVI in asymptomatic severe aortic stenosis?
Original Title: Natural history, diagnostic approaches, and therapeutic strategies for patients with asymptomatic severe aortic stenosis. Reference: Généreux P et al. J Am Coll Cardiol. 2016; Epub ahead of print. Given that transcatheter aortic valve replacement (TAVI) is now being prescribed to lower risk patients, some wonder whether it is time to study the benefit<a href="https://solaci.org/en/2016/04/24/tavi-in-asymptomatic-severe-aortic-stenosis/" title="Read more" >...</a>